This article was originally published in Start Up
Xeotron Corp. employs light activation, digital photolithography, and parallel microfluidics in its biochip making process. The company claims that its flexible platform technology will produce DNA, protein and peptide chips at a faster rate and lower cost than its competitors.
You may also be interested in...
CombinatoRx's platform screens combinations of known drugs to find pairs that could deliver a one-two punch to diseases such as cancer and rheumatoid arthritis.
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.
NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.